A4 Sub B

9. (Amended) A method of reducing the risk of a subject becoming infected with a sexually transmitted pathogen, the method comprising contacting the pathogen or cells susceptible to infection by the pathogen in the subject with a pharmaceutical composition consisting essentially of a β-cyclodextrin, thereby reducing the risk of the subject becoming infected with the sexually transmitted pathogen.

A5

13. (Amended) The method of claim 8, wherein the pharmaceutical composition is formulated in a solution, a gel, a foam, an ointment, a cream, a paste, a lubricant, a jelly, or a spray.

14. (Amended) The method of claim 9, wherein the pharmaceutical composition is formulated in a suppository, a film, a vaginal disk, a bioadhesive polymer, a sponge, a diaphragm, a glove, a tampon, a pellet, a tablet, or a condom.

A6

20. (Amended) The method of claim 19, wherein the enveloped virus is an immunodeficiency virus, a T lymphotrophic virus, a herpes virus, a measles virus, or an influenza virus.

A7 Sub B3

23. (Amended) A method of reducing the risk of transmission of a sexually transmitted disease by a subject infected with a sexually transmitted pathogen, the method comprising contacting the pathogen or cells susceptible to infection by the pathogen with a pharmaceutical composition consisting essentially of a β-cyclodextrin, thereby reducing the risk of transmission of the sexually transmitted disease by the subject.

28. (Amended) The method of claim 23, wherein the pharmaceutical composition is formulated in a solution, a gel, a foam, an ointment, a cream, a paste, a lubricant, a jelly, or a spray.

A8

29. (Amended) The method of claim 23, wherein the pharmaceutical composition is formulated in a suppository, a bioadhesive polymer, a vaginal disk, a film, a diaphragm, a glove, a tampon, a pellet, a tablet, or a condom.

A9

34. (Amended) The method of claim 33, wherein the enveloped virus is an immunodeficiency virus, a T lymphotrophic virus, a herpes virus, a measles virus, or an influenza virus.

A10 sub B1

37. (Amended) A pharmaceutical ~~composition, consisting essentially of a~~ β-cyclodextrin.

A11 sub B2

40. (Amended) ~~A~~ composition for reducing the risk of transmission of a sexually transmitted disease, the composition ~~consisting essentially~~ of a solid substrate and a β-cyclodextrin.

Please add the following new claims:

--46. The pharmaceutical composition of claim 37, which is formulated in a solution, a gel, a foam, an ointment, a cream, a paste, a lubricant, a jelly, or a spray.

A12

47. The pharmaceutical composition of claim 37, which is formulated in a suppository, a film, a sponge, a condom, a bioadhesive polymer, a diaphragm, a glove, a pellet, a tablet, or a tampon.

48. The pharmaceutical composition of claim 37, wherein the β-cyclodextrin is in a concentration of 1 mM to 100 mM.

49. The pharmaceutical composition of claim 37, wherein the β-cyclodextrin is in a concentration of 5 mM to 30 mM.

A12 concld

50. The composition of claim 40, wherein the β-cyclodextrin is present in an amount of 0.1 grams to 2 grams.

51. The composition of claim 40, wherein the β-cyclodextrin is present in an amount of 0.25 grams to 0.75 grams.--